CollPlant Biotechnologies Ltd CLGN
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $2.37M, +360.4% YoY · Filed Mar 26, 2026
CollPlant Biotechnologies Ltd (CLGN) files with the SEC under industry code 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.4 million and a net loss of $11.5 million. Free cash flow was -$9.4 million. As of Dec 31, 2025 it held $5.6 million in cash and investments and $2.8 million in total debt.
Revenue
$2.37M
+360.4% vs prior year
Net income
$-11.49M
+30.8% vs prior year
Operating cash flow
$-9.42M
+33.2% vs prior year
Free cash flow
$-9.45M
+35.2% vs prior year
EPS
$-0.94
+35.2% vs prior year
Dividend per share
None
Shares outstanding
12.80M
+11.8% vs prior year
Net cash
$2.75M
FY 2025
Operating margin
-484.3%
FY 2025
Company profile
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
- Listed as
- CLGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Rehovot, Israel
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1631487
- Former names
- CollPlant Biotechnologies Ltd. (until Jun 20, 2019); CollPlant Holdings Ltd. (until Jun 6, 2019)
Other Orthopedic, Prosthetic & Surgical Appliances & Supplies companies
- Intuitive Surgical Inc ISRG
- Edwards Lifesciences Corp EW
- STERIS plc STE
- Zimmer Biomet Holdings, Inc. ZBH
- Smith & Nephew PLC SNN
- Align Technology Inc ALGN
- MSA Safety Inc MSA
- Establishment Labs Holdings Inc. ESTA
All 29 Orthopedic, Prosthetic & Surgical Appliances & Supplies companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.4M | $515,000 | $11.0M | $299,000 | $15.6M |
| Operating income | -$11.5M | -$17.3M | -$7.5M | -$17.1M | $65,000 |
| Net income | -$11.5M | -$16.6M | -$7.0M | -$16.9M | $237,000 |
| Diluted EPS | -$0.94 | -$1.45 | -$0.62 | -$1.53 | $0.02 |
| Operating cash flow | -$9.4M | -$14.1M | -$2.8M | -$13.7M | $2.5M |
| Free cash flow | -$9.4M | -$14.6M | -$3.7M | -$15.0M | $1.1M |
| Total assets | $10.8M | $18.7M | $34.1M | $37.8M | $51.2M |
| Total liabilities | $4.7M | $5.2M | $5.8M | $5.5M | $6.1M |
| Stockholders' equity | $6.1M | $13.5M | $28.3M | $32.3M | $45.1M |
| Cash and investments | $5.6M | $11.9M | $26.7M | $29.7M | $13.1M |
| Total debt | $2.8M | $3.1M | $3.2M | $3.2M | $3.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 5, 2026 | Nov 5, 2026 |
| 6-K | Current report (foreign issuer) | Nov 4, 2026 | Nov 4, 2026 |
| 6-K | Current report (foreign issuer) | Nov 3, 2026 | Nov 3, 2026 |
| 6-K | Current report (foreign issuer) | Nov 2, 2026 | Nov 2, 2026 |
| 6-K | Current report (foreign issuer) | Oct 29, 2026 | Oct 29, 2026 |
| 6-K | Current report (foreign issuer) | Oct 15, 2026 | Oct 15, 2026 |
All 356 CollPlant Biotechnologies Ltd SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.